{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:05:59Z","timestamp":1780473959838,"version":"3.54.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Funding of Double First-rate Discipline Innovation Team","award":["CPU2018GY31"],"award-info":[{"award-number":["CPU2018GY31"]}]},{"name":"Qing Lan Project of Jiangsu Higher Education Institutions","award":["CPU2018GF05"],"award-info":[{"award-number":["CPU2018GF05"]}]},{"name":"National Key Research and Development Project","award":["2019YFC1711000"],"award-info":[{"award-number":["2019YFC1711000"]}]},{"name":"Scientific Research Innovation Program of Jiangsu Graduate","award":["KYCX200676"],"award-info":[{"award-number":["KYCX200676"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03502-w","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:06:46Z","timestamp":1766563606000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Study on the synthesis, physicochemical properties and transdermal absorption of scutellarein prodrugs"],"prefix":"10.1038","volume":"16","author":[{"given":"Ping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-qi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"issue":"8","key":"3502_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong, A. W. et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 157(8), 940\u2013946 (2021).","journal-title":"JAMA Dermatol."},{"issue":"7130","key":"3502_CR2","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/nature05663","volume":"445","author":"M Lowes","year":"2007","unstructured":"Lowes, M., Bowcock, A. & Krueger, J. Pathogenesis and therapy of psoriasis. Nature 445(7130), 866\u2013873 (2007).","journal-title":"Nature"},{"issue":"5","key":"3502_CR3","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.1365-2133.2011.10213.x","volume":"164","author":"R Gniadecki","year":"2011","unstructured":"Gniadecki, R. et al. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br. J. Dermatol. 164(5), 1091\u20131096 (2011).","journal-title":"Br. J. Dermatol."},{"key":"3502_CR4","doi-asserted-by":"crossref","unstructured":"Chamian, F., Lin, S. L. & Lee, E. et al. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J. Transl. Med. (2007).","DOI":"10.1186\/1479-5876-5-27"},{"issue":"3","key":"3502_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jid.2020.08.034","volume":"141","author":"E Contassot","year":"2021","unstructured":"Contassot, E. & French, L. E. Killing two birds with one stone: TNF antagonists downregulate systemic IL-1\u03b2 in psoriasis. J. Investig. Dermatol. 141(3), 476\u2013478 (2021).","journal-title":"J. Investig. Dermatol."},{"key":"3502_CR6","volume":"26","author":"J Zhou","year":"2020","unstructured":"Zhou, J. et al. Indirect regulation and equilibrium of p35 and p40 subunits of interleukin (IL)-12\/23 by ustekinumab in psoriasis treatment. Med. Sci. Monit. 26, e920371 (2020).","journal-title":"Med. Sci. Monit."},{"issue":"4","key":"3502_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/2229-5178.209622","volume":"8","author":"R Torsekar","year":"2017","unstructured":"Torsekar, R. & Gautam, M. M. Topical therapies in psoriasis. Indian Dermatol. Online J. 8(4), 235\u2013245 (2017).","journal-title":"Indian Dermatol. Online J."},{"issue":"1","key":"3502_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13555-015-0068-3","volume":"5","author":"A Jacobi","year":"2015","unstructured":"Jacobi, A., Mayer, A. & Augustin, M. Keratolytics and emollients and their role in the therapy of psoriasis: A systematic review. Dermatol. Therapy 5(1), 1\u201318 (2015).","journal-title":"Dermatol. Therapy"},{"issue":"2","key":"3502_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaad.2010.09.537","volume":"64","author":"GN Stamatas","year":"2011","unstructured":"Stamatas, G. N. et al. Impaired skin barrier function in mild and moderate diaper dermatitis. J. Am. Acad. Dermatol. 64(2), 132 (2011).","journal-title":"J. Am. Acad. Dermatol."},{"issue":"20","key":"3502_CR10","doi-asserted-by":"publisher","first-page":"21569","DOI":"10.1074\/jbc.M401872200","volume":"279","author":"MK Chung","year":"2004","unstructured":"Chung, M. K. et al. TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J. Biol. Chem. 279(20), 21569\u201321575 (2004).","journal-title":"J. Biol. Chem."},{"issue":"5575","key":"3502_CR11","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1126\/science.1073140","volume":"296","author":"AM Peier","year":"2002","unstructured":"Peier, A. M. et al. A heat-sensitive TRP channel expressed in keratinocytes. Science 296(5575), 2046\u20132049 (2002).","journal-title":"Science"},{"issue":"5","key":"3502_CR12","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jid.2016.02.572","volume":"136","author":"VE Scott","year":"2016","unstructured":"Scott, V. E. et al. 534 Defining a mechanistic link between TRPV3 activity and psoriasis through IL-1\u03b1 and EGFR signaling pathways. J. Investig. Dermatol. 136(5), S94\u2013S94 (2016).","journal-title":"J. Investig. Dermatol."},{"issue":"2","key":"3502_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/ng.311","volume":"41","author":"R Nair","year":"2009","unstructured":"Nair, R. et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 41(2), 199\u2013204 (2009).","journal-title":"Nat. Genet."},{"key":"3502_CR14","unstructured":"Wang, Y. J. The mechanism of TRPV3 regulating psoriasis and discovery of TRPV3 selective inhibitor. China Pharmaceutical University (2020)."},{"issue":"5","key":"3502_CR15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.4103\/0250-474X.98981","volume":"73","author":"V Singh","year":"2011","unstructured":"Singh, V. & Chaudhary, A. K. A review on the taxonomy, ethnobotany, chemistry and pharmacology of Oroxylum indicum vent. Indian J. Pharm. Sci. 73(5), 483\u2013490 (2011).","journal-title":"Indian J. Pharm. Sci."},{"issue":"21","key":"3502_CR16","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1016\/j.bmc.2015.09.047","volume":"23","author":"ZH Shi","year":"2015","unstructured":"Shi, Z. H., Li, N. G. & Shi, Q. P. Synthesis of scutellarein derivatives to increase biological activity and water solubility. Bioorg. Med. Chem. 23(21), 6875\u20136884 (2015).","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"3502_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrd2468","volume":"7","author":"J Rautio","year":"2008","unstructured":"Rautio, J. et al. Prodrugs: Design and clinical applications. Nat. Rev. Drug Discov. 7(3), 255\u2013270 (2008).","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"3502_CR18","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1002\/jps.22692","volume":"100","author":"VJ Stella","year":"2011","unstructured":"Stella, V. J. Prodrugs: Some thoughts and current issues. J. Pharm. Sci. 100(10), 4560\u20134560 (2011).","journal-title":"J. Pharm. Sci."},{"issue":"7","key":"3502_CR19","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1211\/jpp.59.7.0002","volume":"59","author":"JJ Wang","year":"2007","unstructured":"Wang, J. J. et al. Ester prodrugs of morphine improve transdermal drug delivery: A mechanistic study. J. Pharm. Pharmacol. 59(7), 917\u2013925 (2007).","journal-title":"J. Pharm. Pharmacol."},{"issue":"12","key":"3502_CR20","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1002\/jps.10239","volume":"91","author":"AL Stinchcomb","year":"2002","unstructured":"Stinchcomb, A. L. et al. Straight-chain naltrexone ester prodrugs: Diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci. 91(12), 2571\u20132578 (2002).","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"3502_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s11095-005-2592-9","volume":"22","author":"HK Vaddi","year":"2005","unstructured":"Vaddi, H. K. et al. Human skin permeation of branched-chain 3-O-Alkyl ester and carbonate prodrugs of naltrexone. Pharm. Res. 22(5), 758\u2013765 (2005).","journal-title":"Pharm. Res."},{"issue":"8","key":"3502_CR22","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1002\/jps.21594","volume":"98","author":"HK Vaddi","year":"2009","unstructured":"Vaddi, H. K. et al. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J. Pharm. Sci. 98(8), 2611\u20132625 (2009).","journal-title":"J. Pharm. Sci."},{"issue":"1\u20132","key":"3502_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ijpharm.2006.09.034","volume":"332","author":"S Majumdar","year":"2007","unstructured":"Majumdar, S. & Sloan, K. B. Topical delivery of N-alkyl-N-alkyloxycarbonylamino methyl (NANAOCAM) prodrugs of theophylline (ThH). Int. J. Pharm. 332(1\u20132), 64\u201371 (2007).","journal-title":"Int. J. Pharm."},{"issue":"7","key":"3502_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3184\/174751914X14017253941699","volume":"38","author":"W Zhang","year":"2014","unstructured":"Zhang, W. et al. Hydrolysis of scutellarin and related glycosides to scutellarein and the corresponding aglycones. J. Chem. Res. 38(7), 396\u2013398 (2014).","journal-title":"J. Chem. Res."},{"key":"3502_CR25","unstructured":"Williams, A. C. Transdermal and Topical Drug Delivery: From Theory to Clinical Practice; Pharmaceutical Press: London, UK, 2003; pp. 1\u2013242."},{"issue":"12","key":"3502_CR26","doi-asserted-by":"publisher","first-page":"20780","DOI":"10.3390\/molecules191220780","volume":"19","author":"N David","year":"2014","unstructured":"David, N. Prodrug strategies for enhancing the percutaneous absorption of drugs. Molecules 19(12), 20780 (2014).","journal-title":"Molecules"},{"key":"3502_CR27","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1177\/1535370216647183","volume":"241","author":"DQ Luo","year":"2016","unstructured":"Luo, D. Q. et al. Different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models. Exp. Biol. Med. 241, 1733 (2016).","journal-title":"Exp. Biol. Med."},{"key":"3502_CR28","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/rheumatology\/kem055","volume":"8","author":"FL Liu","year":"2007","unstructured":"Liu, F. L. et al. Interleukin (IL)-23 p19 expression induced by IL-1\u03b2 in human fibroblast-like synoviocytes with rheumatoid arthritis via active nuclear factor-\u03baB and AP-1 dependent pathway. Rheumatology 8, 1266\u20131273 (2007).","journal-title":"Rheumatology"},{"issue":"4","key":"3502_CR29","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","volume":"34","author":"MA Lowes","year":"2013","unstructured":"Lowes, M. A. et al. The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol. 34(4), 174\u2013181 (2013).","journal-title":"Trends Immunol."},{"issue":"3","key":"3502_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1515\/tsd-2022-2422","volume":"59","author":"N Bhaskaran","year":"2022","unstructured":"Bhaskaran, N. et al. Development of cream to enhance the antifungal activity and reduce the side effects of fluconazole for the treatment of Candida albicans. Tenside Surfactants Deterg. 59(3), 231\u2013239 (2022).","journal-title":"Tenside Surfactants Deterg."},{"key":"3502_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jaut.2017.11.002","volume":"89","author":"ZR Shi","year":"2018","unstructured":"Shi, Z. R. et al. Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis. J. Autoimmun. 89, 30\u201340 (2018).","journal-title":"J. Autoimmun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03502-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03502-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03502-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:40:29Z","timestamp":1780472429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03502-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3502"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03502-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in strict accordance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments). All experimental protocols were approved by the Institutional Animal Care and Use Committee (#SYXK 2016-0011) of China Pharmaceutical University, and all efforts were made to minimize animal suffering. The ARRIVE guidelines were followed to ensure a comprehensive and transparent reporting of the methodology and findings of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ARRIVE guidelines"}}],"article-number":"3277"}}